<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Gilead to Test Remdesivir Delivered Through Inhalation
Image Overlay - Gilead to Test Remdesivir Delivered Through Inhalation

Gilead to Test Remdesivir Delivered Through Inhalation

July 3, 2020

Gilead to Test Remdesivir Delivered Through Inhalation

Gilead will begin testing an inhaled version of their leading COVID-19 treatment, Remdesivir. It is currently administered to patients intravenously in a hospital setting, though delivery via a nebulizer is decidedly more patient-centric. Regardless of dosage form, Yourway has the means to transport, store, and ship even the most sensitive clinical trial samples globally.

 Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Clinical Trial Supply New England

April 14-15, 2026
Boston, MA

GCSG 2026 US Conference

April 27-29, 2026
San Diego, CA

Media

Articles

White-Glove by Design: The Yourway Standard in Clinical Logistics

Open chat
Come chat with us!
Hello! How can I help you?